Nerandomilast offers potential benefits beyond reduction in FVC decline for patients with IPF and PPF
13 May 2026
byProf. Philip Molyneaux, Imperial College, London, UK
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are aggressive forms of interstitial lung diseases (ILDs), characterized by ongoing fibrosis, progressive lung function decline, and early mortality. While current antifibrotics (nintedanib and pirfenidone) slow disease progression, there remains a need for therapies offering stronger disease control and improved survival. At the 2025 Autumn Respiratory Seminar in Hong Kong, Professor Philip Molyneaux of Imperial College London, UK, highlighted recent data on nondominant, a selective phosphodiesterase 4B (PDE4B) inhibitor that slows lung function decline and shows a reduced risk of death, representing a major advance in IPF and PPF.
